Morgan Stanley
INAB icon

Morgan Stanley’s IN8bio INAB Stock Holding History

Morgan Stanley’s Portfolio INAB Stock Details INAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-34
Closed -$80 – 8394
2025
Q4 		$80 Buy
+34
New +$65 ﹤0.01% 7731
2022
Q4 		– Sell
-50
Closed -$3K – 7923
2022
Q3 		$3K Buy
50
+17
+52% +$1.14K ﹤0.01% 7386
2022
Q2 		$2K Sell
33
-64
-66% -$5.41K ﹤0.01% 7589
2022
Q1 		$10K Buy
97
+33
+52% +$3.69K ﹤0.01% 7398
2021
Q4 		$8K Buy
64
+57
+814% +$11.3K ﹤0.01% 7532
2021
Q3 		$1K Buy
+7
New +$1.74K ﹤0.01% 7778

Other funds holding INAB

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Morgan Stanley's INAB Position: Q1 2026 in Review

Morgan Stanley sold out of IN8bio (INAB) in Q1 2026, closing a stake of 34 shares — an estimated $80 sold.

Morgan Stanley first reported a position in INAB in Q3 2021 and held it in 6 quarters. The position peaked at $10K in Q1 2022. 19 funds tracked by Wall St. Rank hold INAB as of Q1 2026.

  • Morgan Stanley reported no remaining IN8bio position as of Q1 2026 after selling out during the quarter.
  • Morgan Stanley sold 34 IN8bio shares in Q1 2026, an estimated $80.
  • Morgan Stanley first reported a position in IN8bio in Q3 2021 and held it in 6 quarters.
  • Morgan Stanley's IN8bio position peaked at $10K in Q1 2022.
  • 19 funds tracked by Wall St. Rank held IN8bio as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.